FrancophonIA/ELRC3.0 huggingface dataset:
English: What Neparvis looks like and contents of the pack Neparvis 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Danish: Neparvis 24 mg/26 mg filmovertrukne tabletter er violet-hvide ovale tabletter med ”NVR” på den ene side og ”LZ” på den anden side.
English: • if your kidney artery has narrowed.
Danish: • hvis du har en forsnævret nyrearterie.
English: If treatment with Neparvis is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of Neparvis (see sections 4.2, 4.3 and 4.5).
Danish: Hvis behandling med Neparvis afbrydes, må behandling med ACEhæmmer ikke påbegyndes før 36 timer efter sidste dosis Neparvis (se pkt.
English: How to take Neparvis
Danish: Sådan skal du tage Neparvis
English: There is limited experience in patients not currently taking an ACE inhibitor or an ARB or taking low doses of these medicinal products, therefore a starting dose of 24 mg/26 mg twice daily and slow dose titration (doubling every 3-4 weeks) are recommended in these patients (see “Titration” in section 5.1).
Danish: Derfor anbefales en startdosis på 24 mg/26 mg to gange daglig samt langsom dosistitrering (fordobling hver 3.-4. uge) hos disse patienter (se ”Titration” under pkt.
English: The concomitant use of Neparvis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see section 4.3).
Danish: Anvendelse af Neparvis sammen med produkter indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller hos patienter med nedsat nyrefunktion (eGFR <60 ml/min/1,73 m2) (se pkt.
English: • Severe hepatic impairment, biliary cirrhosis and cholestasis (see section 4.2).
Danish: • Svært nedsat leverfunktion, biliær cirrhose eller cholestase (se pkt.
English: • The combination of Neparvis with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3).
Danish: • På grund af en øget risiko for angioødem er en kombination af Neparvis og en ACE-hæmmer kontraindiceret (se pkt.
English: • Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.4 and 4.5).
Danish: • Brug sammen med lægemidler indeholdende aliskiren hos patienter med diabetes mellitus eller hos patienter med nedsat nyrefunktion (eGFR <60 ml/min/1,73 m2) (se pkt.
English: Light pink ovaloid biconvex film-coated tablet with bevelled edges, unscored, debossed with “NVR” on one side and “L11” on the other side.
Danish: Lys pink, oval, bikonvex filmovertrukken tablet med skrå kant, uden delekærv, præget med ”NVR” på den ene side og ”L11” på den anden.
English: Neparvis must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
Danish: Neparvis må ikke indgives før 36 timer efter behandling med ACE-hæmmer er afbrudt.
English: Effect of gender
Danish: Bivirkninger
English: Neparvis 49 mg/51 mg tablets sacubitril/valsartan
Danish: Neparvis 49 mg/51 mg tabletter sacubitril/valsartan
English: Neparvis 24 mg/26 mg tablets sacubitril/valsartan
Danish: Neparvis 24 mg/26 mg tabletter sacubitril/valsartan
English: Neparvis 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Danish: Neparvis 49 mg/51 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171)
English: Neparvis 97 mg/103 mg tablets sacubitril/valsartan
Danish: Neparvis 97 mg/103 mg tabletter sacubitril/valsartan
English: Neparvis has not been studied in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (see sections 4.3 and 4.4).
Danish: Neparvis er ikke undersøgt hos patienter med svært nedsat leverfunktion, biliær cirrhose eller cholestase (se pkt.
English: Iron oxide yellow (E172)
Danish: Gul jernoxid (E172)
English: Violet white ovaloid biconvex film-coated tablet with bevelled edges, unscored, debossed with “NVR” on one side and “LZ” on the other side.
Danish: Violethvid, oval, bikonvex filmovertrukken tablet med skrå kant, uden delekærv, præget med ”NVR” på den ene side og ”LZ” på den anden.
English: Pale yellow ovaloid biconvex film-coated tablet with bevelled edges, unscored, debossed with “NVR” on one side and “L1” on the other side.
Danish: Bleggul, oval, bikonvex filmovertrukken tablet med skrå kant, uden delekærv, præget med ”NVR” på den ene side og ”L1” på den anden.
English: No. at risk Neparvis
Danish: Antal risikopatienter Neparvis
English: Neparvis 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Danish: Neparvis 97 mg/103 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171)
English: Therefore, co-administration of Neparvis with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir,
Danish: Det er derfor muligt, at anvendelse af Neparvis sammen med hæmmere af OATP1B1, OATP1B3 og OAT3 (fx rifampicin, ciclosporin), OAT1 (fx tenofovir, cidofovir) eller MRP2 (fx ritonavir) kan øge den systemiske eksponering af LBQ657 eller valsartan.
English: Renal impairment*
Danish: Nedsat nyrefunktion*
English: MARKETING AUTHORISATION HOLDER
Danish: Betingelser for markedsføringstilladelse
English: Neparvis 24 mg/26 mg film-coated tablets sacubitril/valsartan
Danish: Neparvis 24 mg/26 mg filmovertrukne tabletter sacubitril/valsartan
English: Neparvis 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Danish: Neparvis 24 mg/26 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171)
English: Approximate tablet dimensions 13.1 mm x 5.2 mm Neparvis 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Danish: Neparvis 97 mg/103 mg filmovertrukne tabletter er lyserøde ovale tabletter med ”NVR” på den ene side og ”L11” på den anden side.
English: Neparvis 97 mg/103 mg film-coated tablets sacubitril/valsartan
Danish: Neparvis 97 mg/103 mg filmovertrukne tabletter sacubitril/valsartan
English: Each film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: Hver filmovertrukken tablet indeholder 48,6 mg sacubitril og 51,4 mg valsartan (som sacubitrilvalsartan-natriumsaltkompleks).
English: Neparvis 49 mg/51 mg film-coated tablets sacubitril/valsartan
Danish: Neparvis 49 mg/51 mg filmovertrukne tabletter sacubitril/valsartan
English: • low level of sugar in the blood (shown in a blood test)
Danish: • lavt blodsukkerniveau (påvist i en blodprøve)
English: ACE inhibitor therapy must not be started until 36 hours after the last dose of Neparvis (see sections 4.2 and 4.3).
Danish: Behandling med ACE-hæmmer må ikke påbegyndes før 36 timer efter den sidste dosis Neparvis (se pkt.
English: • The combination of Neparvis with direct renin inhibitors such as aliskiren is not recommended (see section 4.5).
Danish: • Det frarådes at give Neparvis sammen med en direkte reninhæmmer som fx aliskiren (se pkt.
English: • fainting
Danish: • svimmelhed
English: Each 49 mg/51 mg tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: Hver 49 mg/51 mg tablet indeholder 48,6 mg sacubitril og 51,4 mg valsartan (som sacubitril valsartan natriumsaltkompleks).
English: • high level of potassium in the blood (shown in a blood test)
Danish: • højt indhold af kalium i blodet (påvist i en blodprøve)
English: Each film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: Hver filmovertrukken tablet indeholder 24,3 mg sacubitril og 25,7 mg valsartan (som sacubitrilvalsartan-natriumsaltkompleks).
English: Each 24 mg/26 mg tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: Hver 24 mg/26 mg tablet indeholder 24,3 mg sacubitril og 25,7 mg valsartan (som sacubitril-valsartannatriumsaltkompleks).
English: o Each 24 mg/26 mg film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: o Hver 24 mg/26 mg filmovertrukken tablet indeholder 24,3 mg sacubitril og 25,7 mg valsartan (som sacubitril-valsartan- natriumsaltkompleks).
English: o Each 49 mg/51 mg film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: o Hver 49 mg/51 mg filmovertrukken tablet indeholder 48,6 mg sacubitril og 51,4 mg valsartan (sacubitril-valsartan-som natriumsaltkompleks).
English: Each film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: Hver filmovertrukken tablet indeholder 97,2 mg sacubitril og 102,8 mg valsartan (som sacubitrilvalsartan-natriumsaltkompleks).
English: • low level of potassium in the blood (shown in a blood test)
Danish: • lavt indhold af kalium i blodet (påvist i en blodprøve)
English: As there is very limited clinical experience in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) (see section 5.1) Neparvis should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended.
Danish: Da der er meget begrænset klinisk erfaring hos patienter med svært nedsat nyrefunktion (eGFR <30 ml/min/1,73 m2) (se pkt.
English: Dizziness
Danish: Udslæt
English: Each 97 mg/103 mg tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: Hver 97 mg/103 mg tablet indeholder 97,2 mg sacubitril og 102,8 mg valsartan (som sacubitril valsartan natriumsaltkompleks).
English: o Each 97 mg/103 mg film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Danish: o Hver 97 mg/103 mg filmovertrukken tablet indeholder 97,2 mg sacubitril og 102,8 mg valsartan (som sacubitril-valsartan-natriumsaltkompleks).
English: If you take more Neparvis than you should
Danish: Hvis du har taget for meget Neparvis
English: • Concomitant use with ACE inhibitors (see sections 4.4 and 4.5).
Danish: • Brug sammen med ACE-hæmmere (se pkt.
English: Impaired renal function
Danish: Nedsat nyrefunktion
English: • dizziness
Danish: • træthed
English: No. at risk
Danish: • ACE-hæmmere.
English: • spinning sensation
Danish: • nedsat nyrefunktion
English: What Neparvis is and what it is used for What you need to know before you take Neparvis How to take Neparvis
Danish: Det skal du vide, før du begynder at tage Neparvis Sådan skal du tage Neparvis Bivirkninger
English: Impaired hepatic function
Danish: Nedsat leverfunktion
English: This overview was last updated in 03-2019.
Danish: Denne oversigt blev sidst ajourført i 03-2019.
English: Revolade received a marketing authorisation valid throughout the EU on 11 March 2010.
Danish: Revolade fik en markedsføringstilladelse med gyldighed i hele EU den 11. marts 2010.
English: ITP in adults
Danish: ITP hos voksne
English: ITP in children
Danish: ITP hos børn
English: Further information on Revolade can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Revolade.
Danish: Yderligere information om Revolade findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/Revolade.
English: Revolade is a medicine that is used for the treatment of:
Danish: Revolade er et lægemiddel, der anvendes til behandling af:
English: Other information about Revolade
Danish: Andre oplysninger om Revolade
English: As for all medicines, data on the use of Revolade are continuously monitored.
Danish: Som for alle lægemidler bliver data vedrørende brug af Revolade løbende overvåget.
English: The European Medicines Agency decided that Revolade's benefits are greater than its risks and recommended that it be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Revolade opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: For more information about using Revolade, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Revolade, se indlægssedlen eller kontakt lægen eller apotekspersonalet.
English: What measures are being taken to ensure the safe and effective use of Revolade?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Revolade?
English: Preliminary data from a supportive study are consistent with the result of the main study, with 46% of patients responding to treatment after 12 weeks.
Danish: Foreløbige data fra et supplerende studie stemmer overens med resultatet af hovedstudiet, idet 46 % af patienterne responderede på behandling efter 12 uger.
English: An overview of Revolade and why it is authorised in the EU
Danish: En oversigt over Revolade, og hvorfor det er godkendt i EU
English: Revolade is available as tablets (12.5, 25, 50 and 75 mg) and as a powder (25 mg) to prepare a suspension (a liquid) to be taken by mouth.
Danish: Revolade fås som tabletter (12,5, 25, 50 og 75 mg) og som pulver (25 mg) til fremstilling af en suspension (en væske) til indtagelse gennem munden.
English: Side effects reported with Revolade are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Revolade vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne.
English: An extension of the study found that Revolade was effective at maintaining adequate levels of platelets in the long term.
Danish: En forlængelse af studiet viste, at Revolade var effektivt til at opretholde et passende antal blodplader på lang sigt.
English: Revolade contains the active substance eltrombopag.
Danish: Revolade indeholder det aktive stof eltrombopag.
English: What is Revolade and what is it used for?
Danish: Hvad er Revolade, og hvad anvendes det til?
English: For ITP and aplastic anaemia, a lower starting dose should be used in patients of Asian descent (such as Chinese, Japanese, Korean or Taiwanese people).
Danish: Til behandling af ITP og aplastisk anæmi bør der anvendes en lavere startdosis til patienter af asiatisk (såsom kinesisk, japansk, koreansk eller taiwansk) oprindelse.
English: Why is Revolade authorised in the EU?
Danish: Hvorfor blev Revolade godkendt i EU?
English: Severe aplastic anaemia
Danish: Svær aplastisk anæmi
English: For the treatment of thrombocytopenia associated with hepatitis C, two main studies involving a total of 1,441 adults were carried out.
Danish: Til behandling af trombocytopeni forbundet med hepatitis C blev der udført to hovedstudier, som omfattede i alt 1.441 voksne.
English: The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating blood diseases or chronic hepatitis C and its complications.
Danish: Lægemidlet udleveres kun efter recept, og behandlingen skal indledes og overvåges af en læge med erfaring i behandling af blodsygdomme eller hepatitis C og komplikationer forbundet hermed.
English: For the treatment of severe aplastic anaemia, Revolade was studied in 43 patients and it was not compared with any other medicine.
Danish: Til behandling af svær aplastisk anæmi blev Revolade undersøgt hos 43 patienter, og det blev ikke sammenlignet med andre lægemidler.
English: In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment.
Danish: I begge studier blev virkningen hovedsagelig målt på antallet af patienter, hvis blodprøver ikke viste nogen tegn på hepatitis C-virus seks måneder efter behandlingens afslutning.
English: Patients should not take medicines such as antacids or dairy products and mineral supplements in the 4 hours before and in the 2 hours after taking Revolade.
Danish: Patienterne bør ikke indtage lægemidler såsom antacider (syreneutraliserende midler), mælkeprodukter eller mineraltilskud i fire timer før eller to timer efter, at de har taget Revolade.
English: Revolade is used in patients from 1 year of age who have had the disease for at least 6 months and for whom treatment with medicines such as corticosteroids or immunoglobulins has not worked;
Danish: Revolade anvendes til patienter i alderen fra 1 år og opefter, som har haft sygdommen i mindst 6 måneder, og hos hvem behandling med lægemidler såsom kortikosteroider eller immunglobuliner ikke har virket
English: In the body, a hormone called ‘thrombopoietin' stimulates the production of platelets by attaching to certain receptors (targets) in the bone marrow.
Danish: I kroppen stimulerer et hormon kaldet "trombopoietin" produktionen af blodplader ved at binde sig til visse receptorer (mål) i knoglemarven.
English: What are the risks associated with Revolade?
Danish: Hvilke risici er der forbundet med Revolade?
English: Thrombocytopenia associated with hepatitis C
Danish: Trombocytopeni forbundet med hepatitis C
English: • thrombocytopenia in adults with chronic (long-term) hepatitis C, a liver disease caused by the hepatitis C virus.
Danish: • trombocytopeni hos voksne med kronisk (langvarig) hepatitis C, som er en leversygdom, der er forårsaget af hepatitis C-virus.
English: The active substance in Revolade, eltrombopag, also attaches to and stimulates the thrombopoietin receptors.
Danish: Det aktive stof i Revolade, eltrombopag, binder sig også til og stimulerer trombopoietinreceptorerne.
English: Revolade is used in adult patients whose disease is not controlled by immunosuppressive therapy (medicines that lower the body's immune defences) and cannot receive haematopoietic stem cell transplantation (where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow).
Danish: Revolade anvendes hos voksne patienter, hvis sygdom ikke kan reguleres med immunsuppressive lægemidler (lægemidler, der mindsker kroppens immunforsvar), og som ikke kan gennemgå hæmatopoietisk stamcelletransplantation (hvor patientens knoglemarv erstattes af stamceller fra en donor med henblik på dannelse af ny knoglemarv).
English: This occurred in around 40% of those taking Revolade (25 out of 63) compared with around 3% (1 out of 29) of those who took placebo.
Danish: Dette indtraf hos 40 % af dem, der tog Revolade (25 ud af 63), sammenlignet med ca. 3 % (1 ud af 29) af dem, der tog placebo.
English: Important serious side effects are liver problems and thromboembolic complications.
Danish: Vigtige alvorlige bivirkninger er leverproblemer og tromboemboliske komplikationer.
English: In these two studies, a higher proportion of patients who took Revolade tested negative for hepatitis C, compared with those who took placebo (23% versus 14% in the first study, and 19% versus 13% in the second study).
Danish: I disse to studier testede en større andel af de patienter, der tog Revolade, negativt for hepatitis C end dem, der tog placebo (23 % mod 14 % i det første studie og 19 % mod 13 % i det andet studie).
English: In this study, 40% of patients (17 out of 43) responded to treatment after 12 weeks, and in 65% of them (11 out of 17) the platelet count either increased by at least 20,000 per microliter or it was stable without a need for blood transfusions.
Danish: I dette studie reagerede 40 % af patienterne (17 ud af 43) på behandling efter 12 uger, og hos 65 % af disse (11 ud af 17) var blodpladetallet enten steget med mindst 20.000 celler pr. mikroliter eller var stabilt uden behov for blodtransfusioner.
English: The main measure of effectiveness was the number of patients who responded to Revolade (whose platelet, red or white blood cell count remained above pre-set levels) after 12 or 16 weeks of treatment.
Danish: Virkningen blev hovedsagelig målt på antallet af patienter, som responderede på Revolade (hos hvem antallet af blodplader, røde blodceller eller hvide blodceller forblev over de forud fastsatte niveauer) efter 12 eller 16 ugers behandling.
English: Revolade is used when the thrombocytopenia is too severe to allow interferonbased therapy (type of treatment for hepatitis C );
Danish: Revolade anvendes, når trombocytopenien er for alvorlig til, at interferonbaserede behandlinger (behandlinger for hepatitis C) kan anvendes
English: For the treatment of ITP in adults, Revolade was compared with placebo (a dummy treatment) in two main studies involving a total of 311 patients who had previously been treated, but the treatments had not worked or the disease had come back.
Danish: Revolade til behandling af ITP hos voksne blev sammenlignet med placebo (en uvirksom behandling) i to hovedstudier, der omfattede i alt 311 patienter, som tidligere var blevet behandlet, men som ikke havde reageret på behandlingen, eller hvis sygdom var vendt tilbage.
English: The most important serious side effects are febrile neutropenia (low white blood cell counts with fever) and infection.
Danish: De vigtigste alvorlige bivirkninger er neutropeni (et lavt antal hvide blodlegemer med feber) og infektioner.
English: In children with ITP, Revolade was more effective than placebo in one main study involving 92 children between 1 and 17 years of age who had previously been treated for ITP.
Danish: Revolade til behandling af børn med ITP var mere effektivt end placebo i ét hovedstudie, hvori der deltog i alt 92 børn mellem 1 og 17 år, som tidligere var blevet behandlet for ITP.
English: This increases the production of platelets, improving platelet counts.
Danish: Dette øger produktionen af blodplader og derved antallet af dem.
English: For the full list of restrictions and side effects of Revolade, see the package leaflet.
Danish: Den fuldstændige liste over begrænsninger og bivirkninger ved Revolade fremgår af indlægssedlen.
English: • acquired severe aplastic anaemia (a disease in which the bone marrow does not make enough blood cells or platelets).
Danish: • erhvervet svær aplastisk anæmi (en sygdom, hvor knoglemarven ikke producerer nok blodceller eller blodplader).
English: Patients with ITP have low platelet counts in the blood (thrombocytopenia) and are at risk of bleeding.
Danish: Patienter med ITP har et lavt antal blodplader (trombocytopeni) og har risiko for blødning.
English: Revolade was more effective than placebo: in the first study, 59% of the patients who took Revolade (43 out of 73) achieved a platelet count of at least 50,000 per microlitre (which is considered adequate to prevent bleeding complications) after 6 weeks of treatment, compared with 16% of those who took placebo (6 out of 37).
Danish: Revolade var mere effektivt end placebo: I det første studie opnåede 59 % af de patienter, der tog Revolade (43 ud af 73), et blodpladetal på mindst 50.000 pr. mikroliter (hvilket anses for at være tilstrækkeligt til at forebygge blødningskomplikationer) efter seks ugers behandling sammenlignet med 16 % af dem, der fik placebo (6 ud af 37).
English: In the second study, patients taking Revolade were around 8 times more likely than those taking placebo to reach the target platelet count of between 50,000 and 400,000 per microlitre during the 6 months of treatment.
Danish: I det andet studie havde patienter, der tog Revolade, ca. otte gange større sandsynlighed end patienter, der tog placebo, for at opnå et blodpladetal på mellem 50.000 og 400.000 pr. mikroliter i løbet af de seks måneders behandling.
English: What benefits of Revolade have been shown in studies?
Danish: Hvilke fordele viser studierne, at der er ved Revolade?
English: These compared Revolade with placebo for allowing the starting and maintenance of antiviral treatment in patients with hepatitis C whose platelet count was initially too low to allow starting such treatment (less than 75,000 per microlitre).
Danish: I disse studier blev Revolade sammenlignet med placebo med henblik på at indlede og fortsætte antiviral behandling af patienter med hepatitis C, som oprindeligt havde et for lavt blodpladetal til at indlede en sådan behandling (under 75.000 pr. mikroliter).